Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-103 first-in-human dose-escalation and expansion study in advanced NOTCH-altered cancers
NL-OMON48760Phase 1Withdrawn
- Sponsor
- Cellestia Biotech
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of limantrafin in Nonhematologic neoplasms, hematopoietic malignancies, breast cancer and 18 more (2 arms), sponsored by Cellestia Biotech. Primary endpoints: Maximum tolerated dose or recommended Phase II dose and Preliminary antitumor activity. Planned start Jul 2017; status: withdrawn.
02
Drugs
limantrafin
03
Conditions
Nonhematologic neoplasmshematopoietic malignanciesbreast cancercolorectal cancer (CRC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NL-OMON48760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48760.